Patient Engagement
Open Forum

Delivering patient engagement beyond aspirations
Brussels, September 18th and 19th

Powered by

About the Forum

PARADIGM, PFMD and EUPATI welcome you to the Patient Engagement Open forum – a two day event where we will explore patient engagement beyond aspirations and work in a multi-stakeholder context to make it happen.

The Forum aims to provide a holistic perspective of patient engagement, the landscape and actors, and foster collaboration and co-creation while breaking down fragmentation and silos that are often present in patient engagement work.

The agenda of the two days offers a deep dive into some ongoing patient engagement work done by many collaborative initiatives. Topics range from tools and recommendations for effective patient engagement, methods for monitoring and evaluation of impact and outcomes in patient engagement activities, and fair market compensation for patient input to interactive sessions on assessing good practices in patient engagement and more.

Why you should attend

Get an in-depth overview of the impactful collaborative work streams in the patient engagement ecosystem and network with 200+ professionals from healthcare industry, patient advocates and organisations, regulatory representatives and nonprofits that are working together to make patient engagement the norm through tools, recommendations, good practices, framework and capacity building.

Highlights of the programme:

Presentations of ongoing patient engagement projects around the world

Interactive sessions where you will get to be involved in the co-creation of the tools shaping the future of patient engagement

Access to resources available now and receive an update about tools expected in the next 12 months

2019 Agenda

Day 1

 9:00

Registration to PARADIGM’s General Assembly for consortium partners (closed event)

Room: Plenary room

10:00

PARADIGM’s General Assembly for PARADIGM consortium partners only (closed event) – Agenda

12:00

Registration Patient Engagement Open Forum / Lunch

Room: Lobby

13:00

Welcome and Official Opening of the Patient Engagement Open Forum

Magda Chlebus (EFPIA) – PARADIGM
Matthew May (EPF) – EUPATI
Nicholas Brooke (The Synergist) – PFMD
Room: Plenary room

13:30

Panel with National and EU HTA and Regulators
Nathalie Bere – EMA
Daniel O’Connor – MHRA
Sandra Garcia Armesto – IACS
Sabine Ettinger – LBI-HTA
Nicola Bedlington (chair) – EPF

Room: Plenary room

14:30

4 Parallel interactive sessions

  • Session 4: Patient Engagement is everybody’s responsibility. How to reach beyond the easy targets? (online session)

16:30

Coffee break

17:00

Capturing takeaway messages from the day – Tamás Bereczky (EUPATI)

Room: Plenary room

18:00

End of Day 1 – Reception with drinks and finger food – Mingle, share your holiday experience, network, work, discuss, and have fun

Room: Lobby

Day 2

8:45

Arrival time

Room: Lobby

9:15

3 Parallel interactive sessions

11:15

Coffee break

Room: Lobby

11:45

Guest Speaker: Maya Zlatanova – FindMeCure

Room: Plenary room

12:15

Capturing takeaway messages from the morning – Mathieu Boudes (EPF) – PARADIGM

Room: Plenary room

12:45

Lunch

Room: Lobby

14:00

15:00

3 Parallel co-creation workshops: 
(In order to ensure an active workshop for all, the number of participants is limited to 40 in each session, and will be chosen by organisers based on the principle of representativeness of stakeholders in each workshop). 

17:00

End of Patient Engagement Open Forum – Farewell drinks

Room: Plenary room

Forum location

About us

The PE Open Forum is jointly organised by PFMD, EUPATI and PARADIGM

A public-private collaboration for better patient engagement co-led by the European Patients’ Forum (EPF) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) and funded by the Innovative Medicines Initiative. It aims to participate to the co-creation of a sustainable framework allowing systematic, meaningful and ethical patient engagement in medicines development. Strong of 34 partners, from patient organisations to pharmaceutical companies, regulators and academic, the project started in March 2018 and will end in August 2020.

+Find out more

Patient Focused Medicines Development (PFMD) was established in October 2015 as an open, independent global coalition of health stakeholders.

PFMD aims to transform the way in which we understand, engage, and partner with patients globally in the design and conducting of research and development of medicines by focusing on unmet patient needs. We are bringing together relevant experts and synergizing disparate but complementary efforts that integrate the voice of the PATIENT across the lifecycle of medicine.

PFMD is driving the culture change and co-producing tools needed to make systematic patient engagement happen. 

+Find out more

The European Patients’ Academy (EUPATI) is a pan-European programme implemented as a public-private partnership by a collaborative multi-stakeholder consortium from the pharmaceutical industry, academia, not-for-profit, and patient organisations. The Academy was started, developed and implemented as a flagship project of the Innovative Medicines Initiative, and continues to be led by the European Patients’ Forum.

EUPATI supports patient engagement in medicines development by providing education and training to patients, industry, and other stakeholders through e-learning, face-to-face training, 19 national platforms, and an online Toolbox currently used by more than 1.9 million people.

+Find out more

Building a global patient engagement framework

In the fast-paced environment, patient engagement is at a turning point and in the last two days, over 250 people have shared their progress, challenges and ideas to turn patient engagement into a systematic practice for all the stakeholders. Nicola Bedlington, Daniel De Schryver and Nicholas Brooke will take us through the learnings from the two days followed by the next steps.

WORKSHOP 3 - THE ROLE OF PATIENTS IN CO-DESIGNING PLAIN LANGUAGE SUMMARIES TO MAXIMISE THE IMPACT AND UNDERSTANDING OF RESEARCH RESULTS

There is a growing need and expectation for plain-language versions of research results that are accessible to patients and the public. This expectation does not come only from the patient community - the new European regulation for Clinical Trials ( that will come into effect in 2020 will make lay summaries of clinical trial results mandatory at the end of any research initiative. However, there is a wealth of other research results, disseminated in medical publications and congress presentations, that falls outside the remit of the EU-mandated clinical trial lay summaries.

Click to see the full session description

WORKSHOP 2 - HOW TO ENGAGE PATIENTS IN THE CLINICAL TRIAL PHASES

This workshop focuses on two specific activities in the clinical trial phases where patients can be involved in the process. By attending this workshop, you will be able to participate in the co-creation of how-to guides on the following topics:
1) how to best engage patients in the clinical trial protocol development, or
2) how to best engage patients in the selection, development and interpretation of clinical outcome assessment (COA) instruments.

Click to see the full session description

WORKSHOP 1 - HOW TO ENGAGE PATIENTS IN EARLY DEVELOPMENT AND PRECLINICAL RESEARCH PHASES OF MEDICINES DEVELOPMENT

Together this Working Group from PFMD has developed a model which encompasses elements that we feel are the key components in collaborating and co-creating with patients to develop a thorough understanding of all aspects of disease experience, patient preference, unmet need and benefit/risk that will ensure the development of a more relevant, robust and acceptable plan leading into the clinical development phase.

Click to see the full session description

SESSION 7: PART 2 CREATING FUTURE PATIENT ENGAGEMENT TOOLS

The participants will bring their collective expertise to influence and inform the construction of new tools which will shape the future of patient engagement, based on previously presented evidence of gaps in Part #1 (session 3). By the end of the session, they will be aware of recently developed materials, and collaboratively have arrived at the direction for future co-creation of the next generation of patient engagement tools. They will also have increased their understanding of priorities and material needed for patient engagement .

Click to see the full session description

SESSION 6: METRICS TO DETERMINE THE SHARED VALUE OF PATIENT ENGAGEMENT

The session will show participants how to monitor and evaluate (their own) patient engagement activities. It will also provide to the participants some practical examples of determined value of patient engagement.

The group will discuss the feasibility, strengths and weaknesses of the developed framework and the menu of metrics for Monitoring and Evaluation of Patient Engagement activities.

Click to see the full session description

SESSION 5: TOOLKIT FOR COMPENSATING PATIENTS AND PATIENT GROUPS FOR THEIR EXPERT INPUT

The session will describe the Fair Market Value initiative, processes and methods undertaken, status, and deliverables, and to share information about lessons learned and next steps for the future. The National Health Council Fair Market Value Calculator Patient Engagement Activities lists will be provided and  participants will be asked to discuss and provide their input from their own European perspective. As a second topic for interactive discussion, challenges still to be resolved will be posed to the group for brainstorming potential solutions.

Click to see the full session description

SESSION 4: PATIENT ENGAGEMENT IS EVERYBODY’S RESPONSIBILITY, HOW TO BEST REACH BEYOND THE EASY TARGETS? (online session)

Antoine de Saint-Exupéry once said that ‘If you want to build a ship, don't drum up people together to collect wood and don't assign them tasks and work, but rather teach them to long for the endless immensity of the sea.’ Isn’t easy to expand this quote to the patient engagement ecosystem? More pragmatically, this session will address the ‘how to go beyond the easy targets when it comes to patient engagement in medicines R&D?’. It is everybody's responsibility, let’s make it more concrete together.

Click to see the full session description

SESSION 3: PART 1 UNDERSTANDING AND PRIORITISING GAPS IN PATIENT ENGAGEMENT PRACTICES AND PROCESSES

During this session, the participants bring their collective expertise to influence and inform the co-prioritisation and refinement of identified gaps in the practices and processes of patient engagement. This work, done through small working groups, interactively and in real-time, will help to inform the co-creation of the next generation of patient engagement tools.

Click to see the full session description

SESSION 2: LEGAL CONTRACTS BETWEEN PATIENTS, PHARMA AND RESEARCHERS - WHERE ARE WE AND WHAT IS MISSING?

Legal agreements for collaboration between pharmaceutical industry and patients and patient organisations has historically been experienced as problematic one-sided by the patient community for multiple reasons. In order to create the conditions for increasing collaborations, this legal barrier is addressed across the Atlantic by several collaborating organisations and multistakeholder partnerships.

Click to see the full session description

SESSION 1: LEARNING FROM GOOD PATIENT ENGAGEMENT PRACTICES AND APPLYING TO YOUR EVERYDAY WORK

The session aims to inspire participants through real examples of patient engagement  good practices from environments involving multiple stakeholders. Moreover it will show how different organisations have used the PFMD Patient Engagement Quality Guidance and the 7 Quality Criteria to elevate their initiatives, teaching participants how to apply the model on their own projects. 

Click to see the full session description